PD-L1 expression in nonclear-cell renal cell carcinoma

被引:246
作者
Choueiri, T. K. [1 ,2 ,3 ]
Fay, A. P. [1 ]
Gray, K. P. [4 ]
Callea, M. [5 ]
Ho, T. H. [6 ]
Albiges, L. [1 ]
Bellmunt, J. [1 ,2 ,3 ]
Song, J. [5 ]
Carvo, I. [5 ]
Lampron, M. [1 ]
Stanton, M. L. [6 ]
Hodi, F. S. [1 ,3 ,7 ]
McDermott, D. F. [3 ,8 ]
Atkins, M. B. [9 ]
Freeman, G. J. [1 ,3 ]
Hirsch, M. S. [3 ,5 ]
Signoretti, S. [3 ,5 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Mayo Clin, Dept Med Oncol, Scottsdale, AZ USA
[7] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02215 USA
[8] Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA 02215 USA
[9] Georgetown Lombardi Comprehens Canc Ctr, Dept Med Oncol, Washington, DC USA
关键词
renal cell carcinoma; nonclear-cell renal cell carcinoma; benign kidney tumors; PD-L1; PD-1; inhibitors; immunotherapy; B7-H1; PROGNOSTICATION; MANAGEMENT; SUNITINIB; FEATURES;
D O I
10.1093/annonc/mdu445
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. In this study, we report that PD-L1 expression occurs in patients with non-ccRCC depending on histology subtype and tumour cell membrane versus immune cell scoring. In addition, we showed that patients with PD-L1-positive tumours appear to have worse clinical outcomes in non-ccRCC .Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as a parts per thousand yen5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P = 0.01) and grade (P = 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P = 0.02 and P = 0.03, respectively). In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.
引用
收藏
页码:2178 / 2184
页数:7
相关论文
共 29 条
[1]   Targeted therapies and the treatment of non-clear cell renal cell carcinoma [J].
Bellmunt, J. ;
Dutcher, J. .
ANNALS OF ONCOLOGY, 2013, 24 (07) :1730-1740
[2]   Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens [J].
Bellmunt, Joaquim ;
Choueiri, Toni K. ;
Fougeray, Ronan ;
Schutz, Fabio A. B. ;
Salhi, Yacine ;
Winquist, Eric ;
Culine, Stephane ;
von der Maase, Hans ;
Vaughn, David J. ;
Rosenberg, Jonathan E. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1850-1855
[3]   T-cell Co-regulatory Molecule Expression in Renal Angiomyolipoma and Pulmonary Lymphangioleiomyomatosis [J].
Boorjian, Stephen A. ;
Sheinin, Yuri ;
Crispen, Paul L. ;
Lohse, Christine M. ;
Leibovich, Bradley C. ;
Kwon, Eugene D. .
UROLOGY, 2009, 74 (06) :1359-1364
[4]  
Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223
[5]   Renal Cell Carcinoma Preface [J].
Choueiri, Toni K. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) :XIII-XIV
[6]   Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions [J].
Chowdhury, Simon ;
Matrana, Marc R. ;
Tsang, Christopher ;
Atkinson, Bradley ;
Choueiri, Toni K. ;
Tannir, Nizar M. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) :853-+
[7]   Renal-cell carcinoma [J].
Cohen, HT ;
McGovern, FJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490
[8]  
Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb
[9]   Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies [J].
Dutcher, Janice P. ;
de Souza, Paul ;
McDermott, David ;
Figlin, Robert A. ;
Berkenblit, Anna ;
Thiele, Alexandra ;
Krygowski, Mizue ;
Strahs, Andrew ;
Feingold, Jay ;
Hudes, Gary .
MEDICAL ONCOLOGY, 2009, 26 (02) :202-209
[10]   Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma [J].
Green, Michael R. ;
Monti, Stefano ;
Rodig, Scott J. ;
Juszczynski, Przemyslaw ;
Currie, Treeve ;
O'Donnell, Evan ;
Chapuy, Bjoern ;
Takeyama, Kunihiko ;
Neuberg, Donna ;
Golub, Todd R. ;
Kutok, Jeffery L. ;
Shipp, Margaret A. .
BLOOD, 2010, 116 (17) :3268-3277